Core Viewpoint - The company announced the resignation of Deloitte as its auditor, effective from November 12, 2025, and appointed Ernst & Young as the new auditor to fill the vacancy until the next annual general meeting [1] Group 1 - Deloitte has resigned from its position as the company's auditor, effective November 12, 2025 [1] - The board of directors has resolved to appoint Ernst & Young as the new auditor based on the recommendation of the audit committee [1] - Ernst & Young will serve as the auditor until the conclusion of the company's next annual general meeting [1]

Core Viewpoint - The company announced the resignation of its auditor, Deloitte, effective November 12, 2025, and appointed Ernst & Young as the new auditor to fill the vacancy until the next annual general meeting [1] Group 1 - Deloitte has resigned from its position as the company's auditor [1] - The resignation will take effect on November 12, 2025 [1] - The board has decided to appoint Ernst & Young as the new auditor based on the recommendation of the audit committee [1] Group 2 - Ernst & Young will serve as the new auditor starting from November 12, 2025 [1] - The appointment of Ernst & Young will last until the conclusion of the company's next annual general meeting [1]

Core Viewpoint - The company has announced the resignation of its auditor, Deloitte, effective November 12, 2025, and has appointed Ernst & Young as the new auditor to fill the vacancy until the next annual general meeting [1] Group 1 - Deloitte has resigned as the company's auditor, with the resignation taking effect on November 12, 2025 [1] - The board has resolved to appoint Ernst & Young as the new auditor, effective from the same date [1] - Ernst & Young will serve until the conclusion of the company's next annual general meeting [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 Transcenta Holding Limited 創勝集團醫藥有限公司 （於開曼群島註冊成立之有限公司） （股份代號：6628） 變更核數師 本公告由創勝集團醫藥有限公司（「本公司」）（連同其附屬公司，統稱「本集團」） 根據香港聯合交易所有限公司證券上市規則第13.51(4)條作出。 核數師辭任 本公司董事（「董事」）會（「董事會」）宣佈，德勤• 關黃陳方會計師行（「德勤」）已辭 任本公司核數師職務，自2025年11月12日起生效，原因為本公司與德勤未能就審 核本集團截至2025年12月31日止財政年度之綜合財務報表之擬議審計費用達成共 識。 本公司審計委員會（「審計委員會」）已審閱德勤以及其他專業會計師事務所提出的 審核費用建議，並已審議彼等各自的經驗、資源分配及截至2025年12月31日止年 度的建議費用。鑒於其他專業會計事務所提出的建議更具競爭力，董事會在獲得 審計委員會的推薦建議後信納，更換 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年10月31日 狀態: 新提交 致：香港交易及結算所有限公司 FF301 公司名稱: 創勝集團醫藥有限公司（以存續方式於開曼群島註冊的有限公司） 呈交日期: 2025年11月6日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 06628 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 10,000,000,000 | USD | | 0.0001 USD | | 1,000,000 | | 增加 / 減少 (-) | | | | | | USD | | | | 本月底結存 | | | 10,000,000,000 | USD | | 0.0001 USD | | 1,000,000 ...

Core Viewpoint - Chuangsheng Group-B (06628) experienced a significant stock price increase following positive clinical trial results for its partner Inhibrx Biosciences, Inc.'s (INBX.US) DR5-targeting antibody, ozekibart, in treating advanced or metastatic, unresectable sarcoma patients [1] Company Summary - Chuangsheng Group's stock rose nearly 10% during trading, closing up 4.75% at HKD 3.09, with a trading volume of HKD 4.006 million [1] - The company holds exclusive development and commercialization rights for ozekibart in China, Hong Kong, Macau, and Taiwan [1] Industry Summary - Inhibrx Biosciences announced positive primary results from a registrational clinical study evaluating the efficacy of ozekibart compared to placebo in patients with advanced or metastatic, unresectable soft tissue sarcoma [1] - Inhibrx plans to submit a marketing application for ozekibart for soft tissue sarcoma indications to U.S. regulatory authorities by the end of June 2026 [1]

Core Viewpoint - Chuangsheng Group-B (06628) experienced a significant stock price increase following positive clinical trial results for its partner Inhibrx Biosciences, Inc.'s drug ozekibart, which is aimed at treating advanced or metastatic, unresectable soft tissue sarcoma [1] Group 1: Stock Performance - Chuangsheng Group-B's stock rose nearly 10% during trading, closing up 4.75% at HKD 3.09, with a trading volume of HKD 4.006 million [1] Group 2: Clinical Research Results - Inhibrx Biosciences, Inc. announced positive primary results from a registrational clinical study of ozekibart, a DR5 agonistic antibody, comparing its efficacy against a placebo in patients with advanced or metastatic, unresectable soft tissue sarcoma [1] - Based on these results, Inhibrx plans to submit a marketing application for the soft tissue sarcoma indication to U.S. regulatory authorities by the end of June 2026 [1] Group 3: Development Rights - Chuangsheng Group holds exclusive development and commercialization rights for ozekibart in China, Hong Kong, Macau, and Taiwan [1]

Core Viewpoint - Chuangsheng Group-B (06628) experienced a significant intraday increase of nearly 10%, currently up 4.75% at HKD 3.09, with a trading volume of HKD 4.006 million [1] Group 1: Company Developments - Chuangsheng Group announced that its partner Inhibrx Biosciences, Inc. (INBX.US) reported positive primary results from the registration clinical study of the DR5 agonistic antibody ozekibart [1] - The study evaluated the efficacy of ozekibart as a monotherapy compared to a placebo in patients with advanced or metastatic, unresectable chondrosarcoma [1] - Based on these results, Inhibrx plans to submit a marketing application for the chondrosarcoma indication to U.S. regulatory authorities by the end of June 2026 [1] Group 2: Market Position - Chuangsheng Group holds exclusive development and commercialization rights for ozekibart in China, Hong Kong, Macau, and Taiwan [1]

Core Viewpoint - Inhibrx Biosciences, Inc. announced positive primary results from the ChonDRAgon clinical study, evaluating the efficacy of ozekibart (INBRX-109) in patients with advanced or metastatic, unresectable chondrosarcoma compared to placebo [1] Group 1: Clinical Study Results - The ChonDRAgon study involved 206 participants and demonstrated significant improvement in progression-free survival (PFS) for chondrosarcoma patients treated with ozekibart [1] - Ozekibart is the first investigational drug to show a significant improvement in PFS in a randomized controlled trial for this patient population [1] Group 2: Regulatory and Market Implications - Inhibrx plans to submit a New Drug Application (NDA) to the U.S. regulatory authorities for ozekibart's chondrosarcoma indication by the end of June 2026 [1] - The company holds exclusive development and commercialization rights for ozekibart in mainland China, Hong Kong, Macau, and Taiwan through its wholly-owned subsidiary, HJB [1] Group 3: Market Context - Currently, there are no approved systemic treatment options for chondrosarcoma, highlighting the potential market value of ozekibart for global patients and in the regions where the company has exclusive rights [1]

Core Viewpoint - Inhibrx Biosciences, Inc. announced positive primary results from the ChonDRAgon clinical study evaluating ozekibart (INBRX-109) for advanced or metastatic, unresectable chondrosarcoma patients, leading to plans for a U.S. regulatory submission by June 2026 [1] Group 1: Clinical Study Results - The ChonDRAgon study involved 206 participants and demonstrated significant improvement in progression-free survival (PFS) for chondrosarcoma patients treated with ozekibart compared to placebo [1] - Ozekibart is the first investigational drug to show a significant improvement in PFS in a randomized controlled trial for this patient population [1] Group 2: Regulatory and Commercial Plans - Inhibrx plans to submit a marketing application for ozekibart for chondrosarcoma to U.S. regulatory authorities by the end of June 2026 [1] - The company holds exclusive development and commercialization rights for ozekibart in mainland China, Hong Kong, Macau, and Taiwan through a licensing agreement with its wholly-owned subsidiary, HJB [1] Group 3: Market Implications - The encouraging clinical data reinforces the value of ozekibart for global patients and in regions where the company has exclusive rights [1] - Currently, there are no approved systemic treatment options for chondrosarcoma, highlighting the potential market opportunity for ozekibart [1]